The Pharma Letter23h
Prevail Partners to invest again in Hemogenyx
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the ...
PharmaTimes1d
ERLEADA shows 23% survival benefit over enzalutamide in prostate cancer study
In a landmark study, Johnson & Johnson has announced that ERLEADA (apalutamide) significantly reduces the risk of death by 23 ...
The Pharma Letter1d
Erleada shows clinically-meaningful improvement in prostate cancer OS
Johnson & Johnson today released results of a landmark real-world head-to-head study showing that Erleada (apalutamide) ...
FiercePharma1d
J&J's Erleada prevails over Astellas, Pfizer’s Xtandi in real-world prostate cancer study
While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...
Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug
Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to ...
JNJ's Erleada Shows Statistically Significant Overall Survival In Metastatic Prostate Cancer
(RTTNews) - Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months ...
J&J prostate cancer therapy outperforms in real-world study
Johnson & Johnson's (JNJ) prostate cancer therapy Erleada outperforms rival treatment from Pfizer (PFE) stellas (ALPMF) in ...